NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

“We have been focused on discovering and engineering novel ultracompact CRISPR systems at Mammoth and are excited to share the first demonstration of robust in vivo extrahepatic editing in a ...

The work, led by Broad senior group leaders Sonia Vallabh and Eric Minikel, as well as Broad core institute member David Liu, is the first demonstration ... development of CRISPR-Cas9 gene editing ...

The work, led by Broad senior group leaders Sonia Vallabh and Eric Minikel, as well as Broad core institute member David Liu, is the first demonstration ... development of CRISPR-Cas9 gene editing ...

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the ...

Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions to organizations in the Long-Term Services and Supports (LTSS), Home and Community-Based Services ...

The FRT scholar will engineer CRISPR proteins and test for a specific application ... Medicine in autoimmune disease ^ This project involves identification and demonstration of gene variants ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...